52 results about "Histone H3" patented technology

The present invention relates to methods of identifying modulators of an interaction between 53BP1 and histone H3 (H3). The present invention also relates to methods of use of inhibitors of an interaction between 53BP1 and H3. The present invention further relates to fragments of 53BP1 and H3, as well as other methods and uses.

The invention discloses a method for changing cell fate, a construct, a method for changing expression quantity and positioning of cell heterochromatin protein HP 1a in cell, a method for changing a structure of cell chromatin, and a method for changing the cell histone H3 methylation and cells thereof. The method for changing the cell fate comprises protein selected from one of following amino acid sequences by the cell overexpression: a)an amino acid sequence shown by at least one of SEQ ID NO: 1-3; b)a part of an amino acid sequence shown by at least one of SEQ ID NO: 1-3; and c)an amino acid sequence having at least 80% of homogeneity with the amino acid sequences shown in the a) or b). The method can be used for using cell overexpression Gadd45 family protein for effectively open the cell chromatin, so that the cell fate can be conveniently and effectively changed, and especially reprogramming of somatic cell can be promoted.

Methods and agents useful for modulating histone proteolysis, stem cell differentiation, and gene transcription and for treating cancer are disclosed. Antibodies or antigen binding fragments that selectively bind to histone-3 cleavage products and are useful for diagnosing cancer and monitoring a subject's response to cancer treatment are also disclosed.

The present invention relates to methods of diagnosing peripheral neuropathies that comprise determining the titer of autoantibodies directed toward particular nervous system antigens. It also provides for substantially purified preparations of specific antigens, namely neuroprotein-1, histone H3 (NP-2), beta -tubulin (NP-3), neuroprotein-4, neuroprotein-5, NP-9 antigen, and SP neural antigen, which may be used in such diagnostic methods.

The invention relates to a signal-enhanced test strip biosensor for detecting histone methylation. The test strip biosensor comprises a bottom plate with viscidity, a nitrocellulose membrane, a colloidal gold pad, an absorbent paper, and a sample pad, wherein the nitrocellulose membrane is attached to the middle part of the bottom plate; a monoclonal antibody of anti-histone H3 and a goat-anti-rat IgG antibody are sprayed on the nitrocellulose membrane; a detection line and a quality control line are respectively formed; the colloidal gold pad is attached to the bottom plate at one side of the nitrocellulose membrane; gold nanoparticle solution doubly marked by c-DNA (deoxyribonucleic acid) and the monoclonal antibody of anti-histone H3 is sprayed on the colloidal gold pad; the absorbent paper is attached to the bottom plate at the other side of the nitrocellulose membrane; the sample pad is attached to the bottom plate; histone extract is firstly dropwise added to the sample pad in detection; then an enhanced probe formed by DNA and gold nanoparticles in a coupling manner is dropwise added. By adopting the test strip biosensor provided by the invention, the histone methylation condition can be simply and rapidly detected; a detection signal is further amplified by the enhanced probe.

The invention discloses a plasmid vector, a building method thereof and an application. PCAMBIA1300 is modified to form the plasmid vector, botryosphaeria dothidea histone H3 gene promoters, botryosphaeria dothidea transcription elongation factor alpha gene promoters and resistance genes are inserted into pCAMBIA1300 multiple cloning sites, and the resistance genes are positioned at downstream positions of the botryosphaeria dothidea transcription elongation factor alpha gene promoters. According to the plasmid vector, segments among botryosphaeria dothidea histone H3 genes and the transcription elongation factor alpha gene promoters are selected, and genes connected at the back can be efficiently started, so that conversion efficiency of the plasmid vector is greatly improved. According to the building method, the botryosphaeria dothidea is efficiently converted by the aid of exogenous genes mediated by agrobacterium tumefaciens, and a feasible scheme is provided for research and development of aspects such as genetic modification of the botryosphaeria dothidea, development of interested genes, drug target genes separating pathogenic fungi and development of gene functions of the botryosphaeria dothidea.

The invention belongs to the technical field of plant transgenic engineering, and particularly relates to application of histone transmethylase gene in regulating and controlling a rice flowering period and a fringe type. The histone transmethylase gene SDG711 is obtain by cloning, and the nucleotide sequence is shown in SEQ ID NO: 1. Through the method of double-strand RNA inhibition, transformation rice corresponding to the histone transmethylase gene is obtained, the phenomenon that the flowering time of the plant is brought forward for about 2 weeks under a long-day condition after the histone transmethylase gene is inhibited is discovered, and the fringe type of the plant is much smaller than that of a wild plant. A detection to the modification condition of the transgenic histone of the transgene shows that the methylation and trimethylation levels of the histone H3K27 of the transgenic plant are obviously changed. By regulating and controlling the rice histone methylated modification and affecting the flowering time and fringe size of rice, the histone transmethylase gene SDG711 can affect the output of the rice.

Imipridones selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and are useful for treating conditions and disorders in need of such modulation, such as cancers. Specifically, the cancer is a midline glioma, a cancer having a histone H3 mutation, or both. In addition, methods of identifying whether a subject having these conditions, is likely to be responsive to a treatment regimen, such as imipridone administration, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as imipridone administration, monitoring, or providing a prognosis for a subject with these condition are also provided.

The invention relates to a primer and a probe for a fluorescence quantitative PCR of phomopsis amydalina TaqMan. The primer is characterized by comprising a primer pair formed by an upstream primer histone H3-F shown as the SEQ ID No:1 and a downstream primer histone H3-R shown as the SEQ ID No:1. The probe used for detecting phomopsis amydalina is a probe histone H3-P shown as the SEQ ID No:1. The end 5' of the probe histone H3-P marks a fluorescence reporter group FAM, and the end 3' of the probe histone H3-P marks a fluorescence quenching group TAMRA. A method for detecting phomopsis amydalina is characterized by comprising the steps that 1, the upstream primer histone H3-F, the downstream primer histone H3-R and the probe histone H3-P are synthesized, and the probe histone H3-P is marked; 2, genome DNA of a sample to be detected is extracted, and amplification is performed with the upstream primer histone H3-F and the downstream primer histone H3-R to obtain an amplification product; 3, a fluorescence quantitative PCR detection system is adopted for detecting the sample to be detected. The primer and the probe are suitable for fluorescence quantitative PCR detection of phomopsis amydalina TaqMan, and rapidity, sensitivity, simplicity and convenience are achieved.

The present invention provides in vitro methods for detecting, grading or prognosticating cancer, in particular prostate cancer. The invention further provides isolated polynucleotides suitable for reducing or inhibiting the expression of protein kinase C beta I and/or II and/or alpha (and consequently the levels of histone H3 phosphorylated at threonine 6, histone H3 monomethylated at lysine 4, histone H3 dimethylated at lysine 4, histone H3 trimethylated at lysine 4) and further relates to pharmaceutical compositions comprising said polynucleotides for the treatment or prevention of cancer, in particular prostate cancer.

The present invention proposes a novel method for the detection of circulating histones H3 and H2B in plasma from sepsis or septic shock (SS) patients, based on mass spectrometry-based methods, in particular based on multiple reaction monitoring targeted mass spectrometry (MRM-MS). Such methods allow quantification of histones using an internal standard and show strong specificity and sensitivity values.

The invention relates to use of a chidamide analogue LT-548-133-1 ((E)-N-(2-aminophenyl)-4-[[3-(3-chlorophenylmethylene)-2-oxopiperidin-1-yl] methyl] benzamide) in preparation of anti-tumor drugs, andbelongs to the field of biomedical technology. The invention adopts different concentrations of LT-548-133-1 on human breast cancer cell MCF-7. The results showed that LT-548-133-1 up-regulates the acetylation level of histone H3 in a dose-dependent manner while decreasing the expression of p21, resulting in cell cycle arrest in G2/M phase and ultimately in MCF-Cell proliferation is inhibited. The study may provide a new approach for the treatment of tumor rapid proliferation.

The invention discloses a preparation method of targeted extracellular vesicles for treating drug-resistant tumors. The preparation method comprises the following steps: 1, preparing DOX-loaded EVs; 2, preparing a hyaluronic acid derivative with a targeting CD44; and 3, modifying the surface of the DOX-loaded EVs with a hyaluronic acid derivative with targeting CD44. The extracellular vesicles arederived from non-tumor cells and can reduce the acetylation level of histone H3 in a promoter region of a drug-resistant gene ABCB1 by inhibiting protein expression of histone acetylation transferase, so that the expression of drug-resistant protein P-gp is reduced. The invention also relates to targeted modification of extracellular vesicles by using hyaluronic acid connected with octadecyl. Theobtained targeting modified extracellular vesicles are simple in preparation process, good in biocompatibility and good in tumor cell targeting performance as a drug carrier, the permeability in tumor vessels is improved, the tumor drug resistance reversing effect is remarkable, and the targeting modified extracellular vesicles are an excellent drug carrier for treating drug-resistant tumors.

The invention discloses an ANP32A-targeted anti-leukemia small molecule peptide as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The H3BP peptide fragment can competitively block the combination of ANP32A and unmodified histone H3, and can inhibit the function of ANP32A in promoting leukemia cell proliferation. The H3BP is efficiently brought into leukemia cells in a mode of fusing the cell-penetrating peptide and the H3BP by utilizing the characteristic that the cell-penetrating peptide can carry foreign protein to enter the cells, so that the proliferation of the leukemia cells and the progress of diseases are effectively intervened, and a new solution is provided for effective intervention of leukemia.

The invention generally relates to methods for predicting responsiveness of a cancer to an immunotherapeutic agent and methods of treating cancer. More specifically, the invention relates in part to the use of histone H3 lysine (27) trimethylation (H3K27me3), E-cadherin, and other biomarkers to treat cancer and determine the responsiveness of a cancer tumor to treatment with an immunotherapeutic agent.

The invention discloses a CARM1 small-molecule inhibitor and application thereof. The small-molecule inhibitor can effectively inhibit the proliferation of prostate cancer cells. The provided CARM1 small-molecule inhibitor has the low toxicity to normal cells and has the significant inhibitory effect on CARM1-mediated histone H3R17me2a modification and expression of a target gene PSA in the downstream of the histone, the proliferation of tumor cells can be effectively inhibited, and thus the CARM1 small-molecule inhibitor is expected to be developed into a new antitumor drug; and the in vitroand vivo therapeutical effects on prostate cancer, non-small cell lung cancer, breast cancer, acute and chronic leukemia, liver cancer, stomach cancer, colorectal cancer, ovarian cancer, cervical cancer are achieved.

Karounitriol is an important active ingredient from Semen Trichosanthis which is a traditional Chinese medicinal material. The invention introduces a new function of the karounitriol. Through action experiment on primary cultured neuron of a rat, the expression level of an EZH1 gene can be reduced by adding the karounitriol. The EZH 1 is a key enzyme causing methylation of histone H3, methylation of histone is an important constituent part of epigenetics, and change of the histone shows that a nervous system has global stress reaction on the karounitriol, and the karounitriol has remarkable regulating effect on activity of the nervous system.

The invention discloses an application of a CIT-H3 protein detection reagent in preparation of a liver cancer prognosis and/or recurrence prediction reagent, and provides an immunohistochemical detection kit for evaluating the prognosis and recurrence risk of a liver cancer patient. According to the principle of immunohistochemistry, the kit detects a marker CIT-H3 (citrullinated histone H3) of a neutrophile granulocyte extracellular trap net, has the characteristics of being objective, accurate, simple, convenient, intuitive, easy to operate and the like, and can be operated by common technicians in a hospital pathology room without the help of complex instruments; the prognosis and recurrence risk of the liver cancer patient can be effectively evaluated, so that a doctor is better helped to monitor the condition of the patient, proper treatment means are adjusted in time, the treatment effect is improved, and the survival time of the patient is prolonged.

The present invention relates to non-transgenic and transgenic plants, preferably crop plants, having biological activity of a haploid inducer and comprising a polynucleotide which comprises a nucleotide sequence encoding a centromer histone H3 (CENH3) protein, wherein the polynucleotide comprises at least one mutation causing an alteration of the amino acid sequence of the CENH3 protein, and to a part of the part. Further, the invention provides methods of generating the inducer plants, methods of generating haploid and double haploid plants using the inducer plants as well as methods of facilitating cytoplasm exchange.

The present invention relates to novel application of a product for detection of phosphorylation status of human histone H3 Ser10 and Ser28. The phosphorylation status of the human histone H3 Ser10 can be used for identification or assistant identification of the number of male pronucleus in human embryos, the period development of the human embryos and the growth period of human oocytes, or screening of the human embryos or human zygotes; the phosphorylation status of the H3Ser28 can be used for identification or assistant identification of the period development of the human embryos and thegrowth period of the human oocytes, or screening of the human embryos or the human zygotes.